

EASE your burden of COVID-19 diagnosis



immtek)

COVID-19

Antigen Rapid Test





What's COVID-19


COVID-19 is a respiratory illness caused by the novel coronavirus named "Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]" that was discovered in Wuhan, China 2019, and it is currently a World Health Organization (WHO) declared pandemic. People with SARS-CoV-2 infection may be asymptomatic but still could transmit it through respiratory droplets from coughs and sneezes.¹

Symptoms and signs of COVID-19 are non-specific, however in symptomatic individuals most commonly include fever, cough, fatigue, and shortness of breath. Severe patients may progress to acute respiratory distress syndrome [ARDS], septic shock, diffuse alveolar damage [DAD], and death.²

In addition to maintaining good personal hygiene, the rapid diagnosis of COVID-19 is critical for prevention and control of this pandemic.

Diagnostic Solutions

The ImmTek™ COVID-19 product line aims to ease the burden of diagnosis on health facilities. We hope each product category can play a critical and complementary role in response to COVID-19 pandemic from early-stage detection to epidemiological surveillance, and assist health facilities to efficiently improve patient management, public health decisions, and ensure timely treatment of patients.



EASE Your Burden of COVID-19 Diagnosis



Visible and reliable result appears in 10 minutes.

ccurate interpretation

No cross-reactivity to MERS and other common human coronaviruses.

imple procedure

One step, no equipment required.

fficient POCT

Minimizes specimen degradation or contamination during transportation and storage.





Intended Use

ImmTek™ COVID-19 Antigen Rapid Test is an in vitro immunochromatographic assay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigen in nasal or nasopharyngeal swab specimens from individuals with suspected symptoms within 5 days, as an aid to the initial diagnosis of SARS-CoV-2 infection. Test results should be interpreted by medical professionals in conjunction with clinical history and symptoms.







Health

Hotel

Airport Station







Specification

Test Principle

Target Antigen

Specimen Type

Reaction Time

Interpretation

Limit of Detection

Cross Reactivity

Interference

Sensitivity

Specificity

Storage

Lateral Flow Immunochromatographic Assay

SARS-CoV-2 Nucleocapsid Protein

Fresh Nasal or Nasopharyngeal Swab Specimen

10 Minutes

Clear and accurate reading of dual colored C line and T line.

3.13 x 10² TCID₅₀/ml

No cross reactivity with other viruses and bacteria tested.

Not affected by the interfering substances tested.

93.48% [95%CI: 82.10%-98.63%]


99.14% [95%CI: 95.29%-99.98%]


Room Temperature 15-30°C (59-86°F)

Order Information


Catalogue No.	Product Name	Product Type	Package
INFCOV1925C	ImmTek™ COVID-19	Cassette	25 Tests/Box
INFCOV1950S	Antigen Rapid Test	Strip	50 Tests/Box

Specimen Collection





Test Procedure Strip Test Procedure Cassette



Performance

High Sensitivity and Specificity compared to RT-PCR

A total of 162 nasopharyngeal swab specimens collected from 148 symptomatic patients were tested using Immtek™ COVID-19 Antigen Rapid Test. the clinical performance was compared to a FDA EUA molecular assay (RT-PCR).

N=162		RT-PCR	
		Positive	Negative
ImmTek™ COVID-19 Antigen Rapid Test	Positive	43	1
	Negative	3	115






Specificity



Accuracy



Low Limit of Detection (LoD)

The study was performed by testing a 2 fold dilution series of 3 replicates per concentration, and then the final LoD was determined to be the lowest detectable concentration at which at least 95% replicates are positive.

No.	Туре	Strain	Limit of Detection	Result
1	Inactivated SARS-CoV-2 gamma-irradiated	USA-WA1/2020	3.13x10 ² TCID ₅₀ /ml	Positive 20/20
2	SARS-CoV-2 recombinant nucleocapsid protein		30 ng/ml	Positive 20/20

No Cross-reactivity

There was no cross-reactivity with the following bacteria and viruses tested.

Bacteria panel	
Bordetella pertussis	Mycoplasma pneumoniae
Candida albicans	Pseudomonas aeruginosa
Chlamydia pneumoniae	Staphylococcus aureus
Escherichia coli	Staphylococcus epidermidis
Haemophilus influenzae	Streptococcus pneumoniae
Legionella pneumophilla	Streptococcus pyogenes

Virus panel	
Adeno virus type 7	
Adeno virus type 41	
Enterovirus type 68	
Enterovirus type 71	
Human coronavirus 229E	
Human coronavirus NL63	
Human coronavirus OC43	
hMPV 3 type B1	

Human parainfluenza virus (HPIV) Influenza A-H1N1 Influenza A-H3N2 Influenza B-Vic Influenza B-Yam Respiratory syncytial virus Rhinovirus

Not Affected by Interfering Substances

There was no interference from Endogenous/Exogenous interfering substances listed below.

Interference substances	Concentration
Afrin (Oxymetazoline) Aspirin Chloraseptic (Menthol/Benzocaine) CVS Nasal Drops (Phenylephrine) CVS Saline Nasal Spray Dextromethorphan Diphenhydramine HCI Fisherman's Friend Hemoglobin Homeopathic (Alkalol) Hosoon Troches (ROOT) Ibuprofen Mucin Mupirocin Nasal Ointment	15% v/v 20 mg/ml 1.5 mg/ml 1.5% v/v 15% v/v 10 mg/ml 5 mg/ml 1.5 mg/ml 20 mg/ml 1:10 dilution 20 mg/ml 20 mg/ml 0.50% 10 mg/ml

Interference substances	Concentration
Nasal Washing Salt	20 mg/ml
Naso GEL (NeilMed)	5% v/v
Nasal Gel (Oxymetazoline)	10% v/v
NASONEX Aqueous Nasal Spray	10%
Oxymetazoline HCI	10 mg/ml
Phenylephrine HCl	100 mg/ml
Ponstan	20 mg/ml
Ricola (Menthol)	1.5 mg/m l
Sore Throat Phenol Spray	15% v/v
Swinin nasal sprays	10%
Tamiflu (Oseltamivir Phosphate)	5 mg/ml
Tobramycin	4 μg/ml
Whole Blood	4%
Zicam	5% v/v

Reference:

- 1. Z. Hu, C. Song, C. Xu. et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020; 63[5]: 706-711.
- 2. How to Protect Yourself & Others. Centers for Disease Control and Prevention (CDC). 8 April 2020. Archived from the original on 26 February 2020. Retrieved 9 April 2020.
- 3. L. Liu, W. Liu, Y. Zheng. Et al. A preliminary study on serological assay for severe acute 2 respiratory syndrome coronavirus 2 [SARS-CoV-2] in 238 admitted hospital patients. Microbes and Infection. 8 March 2020.
- 4. B. Aylward, W. Liang. et al. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19).16-24 February 2020.

For more information and assistance, please contact us or your local sales representative.

We are with you to combat COVID-19 together in these challenging times!



METAS BIOMEDICAL INC.

Headquarter: 1F., No.72, Minle St., Chiayi 60050, Taiwan, R.O.C. Contact: 3F., No. 616, Zhongshan Rd., Chiayi 60041, Taiwan, R.O.C.

Tel: 886-5-2160700

E-mail: info@metasbiomedical.com Website: www.metasbiomedical.com